Koethe Dagmar, Gerth Christoph W, Neatby Miriam A, Haensel Anita, Thies Martin, Schneider Udo, Emrich Hinderk M, Klosterkötter Joachim, Schultze-Lutter Frauke, Leweke F Markus
Department of Psychiatry and Psychotherapy, University of Cologne, 50924 Cologne, Germany.
Schizophr Res. 2006 Dec;88(1-3):142-50. doi: 10.1016/j.schres.2006.07.023. Epub 2006 Sep 26.
Recent data on alterations of the endogenous cannabinoid system in schizophrenia have raised the question of its functional role in this disease. The psychoactive compound of Cannabis sativa, delta-9-tetrahydrocannabinol (Delta9-THC), has been shown to induce psychotic symptoms, but it is unknown to what extend prodromal states of psychoses are reflected by these experimental approaches. This study compares four groups of subjects: antipsychotic-naïve patients suffering from acute paranoid schizophrenic or schizophreniform psychosis (SZ), patients in the prodromal state (IPS), healthy controls without any pharmacological intervention (HC) and a second group of healthy volunteers who were orally administered synthetic Delta9-THC (Dronabinol) (HC-THC). Neither SZ and IPS nor HC received the experimental drug. All subjects were assessed using the Brief Psychiatric Rating Scale (BPRS) and the Binocular Depth Inversion Illusion Test (BDII). The latter represents a sensitive measure of impaired visual information processing that manifests in various experimental and naturally occurring psychotic states. BDII values were well comparable in SZ, IPS and HC-THC, and all groups differed significantly to HC. The BPRS revealed no significant difference between HC-THC and IPS while both were significantly different from SZ and HC, respectively. Our results suggest that Delta9-THC-induced altered states of consciousness may serve as a useful tool for modeling psychotic disorders, particularly their prodromal states. Furthermore, they provide insight into the perceptual and psychopathological alterations induced by Delta9-THC, which is essential for the understanding of the pro-psychotic effects of herbal cannabis preparations with highly enriched Delta9-THC content.
近期关于精神分裂症内源性大麻素系统改变的数据引发了其在该疾病中功能作用的问题。大麻的精神活性化合物Δ⁹-四氢大麻酚(Delta9-THC)已被证明可诱发精神病症状,但这些实验方法在多大程度上反映了精神病的前驱状态尚不清楚。本研究比较了四组受试者:患有急性偏执型精神分裂症或精神分裂样精神病(SZ)且未服用过抗精神病药物的患者、前驱期患者(IPS)、未接受任何药物干预的健康对照组(HC)以及口服合成Delta9-THC(屈大麻酚)的另一组健康志愿者(HC-THC)。SZ组、IPS组和HC组均未接受实验药物。所有受试者均使用简明精神病评定量表(BPRS)和双眼深度反转错觉测试(BDII)进行评估。后者是视觉信息处理受损的一种敏感测量方法,在各种实验性和自然发生的精神病状态中均有体现。SZ组、IPS组和HC-THC组的BDII值具有良好的可比性,且所有组与HC组均有显著差异。BPRS显示HC-THC组和IPS组之间无显著差异,而这两组分别与SZ组和HC组有显著差异。我们的结果表明,Delta9-THC诱导的意识改变状态可能是模拟精神障碍,特别是其前驱状态有用的工具。此外,它们还提供了对Delta9-THC诱导的感知和精神病理学改变的见解,这对于理解Delta9-THC含量高度富集的草药大麻制剂的促精神病作用至关重要。